Share Twitter
Link Tweet
Iframe
Web Intent
TweetEmbed tweet
#ODYSSEY OUTCOME trial results Alirocumab reduces the primary endpoint & all cause death in patients with ACS:NNT 62. Bigger advantage in those with LDL>100 at baseline (NNT 29). Whats your take home? @hect2701@DLBHATTMD@vlgmrc@PCRonline@VijayKunadian@sbrugaletta@Ortega_Pazpic.twitter.com/gkY64AG10E
— Francesco Costa (@Costa_F_8) 10 March 2018
Test PDF